|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02367 GIANT BIOGENE
Nominal 
29.780 +0.100 (+0.337%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 5,518,512 | -0.367% | 5,538,812 | 3,524,143 | 2,364,445 | 1,552,486 |
| Cost of Sales | (1,085,162) | 9.403% | (991,897) | (577,006) | (369,205) | (198,149) |
| Gross Profit | 4,433,350 | -2.498% | 4,546,915 | 2,947,137 | 1,995,240 | 1,354,337 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 592 | -- | (92) | 700 | (614) | (326) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 9,495 | -- | (3,601) | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 2,350,304 | -4.372% | 2,457,754 | 1,745,089 | 1,177,749 | 972,917 | |
| Taxation | (435,642) | 10.003% | (396,027) | (296,887) | (176,163) | (144,785) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 174 | -71.935% | 620 | 3,551 | 439 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 1,914,836 | -7.153% | 2,062,347 | 1,451,753 | 1,002,025 | 828,132 | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (167,373) | 50.640% | (111,108) | (47,379) | (13,138) | (9,408) |
| Depreciation & Amortisation | 82,246 | 66.201% | 49,486 | 34,175 | 27,628 | 24,210 |
| Directors' Emoluments | -- | -- | 23,516 | 16,596 | 14,161 | 13,099 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 183.000 | -12.857% | 210.000 | 149.000 | 99.000 | 83.000 |
| DPS (cts) | 121.040 | -- | 119.420 | 89.000 | 0.000 | -- |
| Dividend Payout Ratio (%) | 66.142% | -- | 56.867% | 59.732% | -- | -- |
| Cash flow per share ($) | -- | -- | 2.079 | 1.687 | 1.325 | 0.710 |
| NBV per share ($) | 9.255 | -- | 6.913 | 4.384 | 2.848 | -- |
| Remarks: | Real time quote last updated: 25/03/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,914,836 |
| %Change | -7.153% |
| EPS / (LPS) | RMB 1.830 |
| NBV Per Share (¥) | RMB 9.255 |